4-Repeat Tauopathy Neuroimaging Initiative – Cycle 2 (4RTNI-2)

What is the study about?

This study follows people with progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) for up to 2 years and compares their brain changes with healthy volunteers of the same age. Researchers hope to learn more about how patients with PSP and CBD progress over time and which measures are best for tracking change and predicting progression. Various measures including brain imaging, cerebrospinal fluid analysis, eye tracking, blood markers and neuropsychological testing will be measured.

 

Eligibility– Who can participate?

Participants must:

• Either have no known history of brain disease (i.e., be a healthy volunteer) or have a diagnosis of corticobasal syndrome or degeneration (CBS or CBD) or progressive supranuclear palsy (PSP)
• Have a reliable study partner who has frequent contact with participants, can come to study visits and provide information about them
• Be willing and able to undergo testing procedures and follow-up visits
• Be able to walk five steps with little help

 

Time requirement

Participants and their caregivers are asked to come every 6 months for up to 24 months. Visits can be done in-person, remotely or through a combination of remote and in-person (hybrid) visits. Each in-person visit will take 2-3 days to complete. Remote visits via video conference can be completed in 4-5 hours and the hybrid visit will take 4-5 hours of remote and 1 full day of in-person visits. Participants will be reimbursed for the time and expenses incurred with the study visits (travel, parking, food).

 

TDRA Investigator

Dr. Carmela Tartaglia

 

More information

https://clinicaltrials.gov/ct2/show/NCT02966145

 

Video

Advances in Dementia Research Webinar- Listen to Dr. Carmela Tartaglia (Principal Investigator) discuss the 4RTNI-2 study in further detail. https://youtu.be/WF0qwQAqpM4

TDRA Site:

University Health Network (UHN)-Toronto Western Hospital

Address: 399 Bathurst Street, Toronto ON M5T 2S8

Age Group:

40 - 49, 50 - 54, 55 - 59, 60 - 64, 65 - 69, 70 - 80, 81 - 85

Target Population:

Corticobasal degeneration (CBD), Corticobasal Syndrome (CBS), Healthy volunteer, Progressive Supranuclear Palsy (PSP)